Literature DB >> 12130502

c-myc proto-oncogene expression in hemophilic synovitis: in vitro studies of the effects of iron and ceramide.

Fei-Qiu Wen1, Adnan A Jabbar, Yi-Xin Chen, Tamara Kazarian, Dharmesh A Patel, Leonard A Valentino.   

Abstract

Hemophilia is a rare congenital bleeding disorder that is due to the deficiency of blood coagulation factor VIII or IX. Recurrent musculoskeletal bleeding is common and bleeding into joints results in a chronic inflammatory condition termed hemophilic synovitis. This destructive process is characterized by hemosiderin deposition in the superficial and deeper layers of the synovial membrane as well as a proliferation of synovial fibroblasts and vascular cells. The hyperplastic synovium and neovascular changes are reminiscent of the histopathologic appearance observed in malignant tissues. Indeed, the benign hyperplastic synovium in patients with hemophilia displays similar invasive and destructive behaviors suggesting the possibility of analogous disturbances in growth control and locally invasive mechanisms. Iron plays a role in malignant cell growth, local invasion, and tumor progression, possibly due to changes in the expression of the proto-oncogene, c-myc. We hypothesized that iron plays a similar role in hemophilic synovitis. To explore this hypothesis, we investigated the in vitro effects of iron on the proliferation of a primary, human synovial fibroblast cell (HSFC) line and the involvement of c-myc in this process. We also examined the role of ceramide, a sphingolipid capable of inducing apoptosis in this model system. HSFC proliferation was increased in a dose-dependent fashion and c-myc expression was enhanced by ferric citrate compared to sodium citrate control. Ceramide prevented both the iron-induced increases in HSFC proliferation and c-myc expression. These results indicate that iron probably plays a role in the proliferative changes observed in hemophilic joint disease and that aberrant expression of c-myc may underlie the iron effects. Furthermore, these results suggest that there may be a therapeutic role for ceramide in reversing these changes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12130502     DOI: 10.1182/blood-2002-02-0390

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  23 in total

1.  TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.

Authors:  Tine Wyseure; Tingyi Yang; Jenny Y Zhou; Esther J Cooke; Bettina Wanko; Merissa Olmer; Ruchi Agashe; Yosuke Morodomi; Niels Behrendt; Martin Lotz; John Morser; Annette von Drygalski; Laurent O Mosnier
Journal:  JCI Insight       Date:  2019-10-03

2.  The importance of genetic factors for the development of arthropathy: a longitudinal study of children and adolescents with haemophilia A.

Authors:  Edward D Gomperts; John Schwarz; Sharyne M Donfield; Alice E Lail; Jan Astermark; W Keith Hoots; Cheryl A Winkler; Erik Berntorp
Journal:  Thromb Haemost       Date:  2016-12-08       Impact factor: 5.249

3.  Joint haemorrhage partly accelerated immobilization-induced synovial adhesions and capsular shortening in rats.

Authors:  Yoshito Onoda; Yoshihiro Hagiwara; Akira Ando; Takashi Watanabe; Eiichi Chimoto; Hideaki Suda; Yutaka Yabe; Yoshifumi Saijo; Eiji Itoi
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2013-09-08       Impact factor: 4.342

4.  Neoangiogenesis contributes to the development of hemophilic synovitis.

Authors:  Suchitra S Acharya; Rosandra N Kaplan; Dan Macdonald; Oluwa T Fabiyi; Donna DiMichele; David Lyden
Journal:  Blood       Date:  2010-12-16       Impact factor: 22.113

5.  Assessing joint involvement in haemophilia by clinical rheumatologic scores. A pilot study on similarities with subjects with psoriatic arthritis.

Authors:  Matteo Nicola Dario Di Minno; Salvatore Iervolino; Rosario Peluso; Antonio del Puente; Anna Russolillo; Antonio Coppola; Carlo Ruosi; Anna Guida; Raffaele Scarpa; Giovanni Di Minno
Journal:  Clin Rheumatol       Date:  2011-02-16       Impact factor: 2.980

6.  EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.

Authors:  Jhansi Magisetty; Usha R Pendurthi; Charles T Esmon; L Vijaya Mohan Rao
Journal:  Blood       Date:  2020-06-18       Impact factor: 22.113

Review 7.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

8.  Vascular remodeling underlies rebleeding in hemophilic arthropathy.

Authors:  Vikas Bhat; Merissa Olmer; Shweta Joshi; Donald L Durden; Thomas J Cramer; Richard Fw Barnes; Scott T Ball; Tudor H Hughes; Mauricio Silva; James V Luck; Randy E Moore; Laurent O Mosnier; Annette von Drygalski
Journal:  Am J Hematol       Date:  2015-10-08       Impact factor: 10.047

Review 9.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

10.  Components in Plasma-Derived Factor VIII, But Not in Recombinant Factor VIII Downregulate Anti-Inflammatory Surface Marker CD163 in Human Macrophages through Release of CXCL4 (Platelet Factor 4).

Authors:  Anne Bertling; Martin F Brodde; Mayken Visser; Janina Treffon; Michelle Fennen; Anke C Fender; Reinhard Kelsch; Beate E Kehrel
Journal:  Transfus Med Hemother       Date:  2017-08-11       Impact factor: 3.747

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.